Australian Doctor Australian Doctor 15th December 2017 | Page 9

Efficacy
Why
choose?
Safety
*Renal impairment (any stage)
Efficacy
1
Established
1
Safety Profile
For a broad range
of T2DM patients*
choose JANUVIA
1-7
with confidence.
*65 years of age
*Long term T2DM
PLEASE REVIEW THE PRODUCT INFORMATION BEFORE PRESCRIBING. PRODUCT INFORMATION IS AVAILABLE AT
WWW.MSDINFO.COM.AU/JANUVIAPI OR WWW.MSDINFO.COM.AU/JANUMETPI
PBS INFORMATION: Dual, Triple, Insulin add on therapy listings. Authority required (Streamlined). Refer to PBS Schedule for full authority information.
Initial combination therapy is not listed on the PBS. Monotherapy is not listed on the PBS
WARNING: Life-threatening lactic acidosis can occur due to accumulation of metformin. Risk factors include renal impairment, old age and the use of high doses
of metformin above 2000 mg per day.
JANUVIA Minimum Product Information (PI) Indications: To improve glycaemic control in patients ≥ 18 years old with Type 2 Diabetes Mellitus. Either as monotherapy (when metformin cannot be used and when dietary and exercise measures have failed), or as dual
combination therapy with metformin or with a sulfonylurea, or with a thiazolidinedione where its use is considered appropriate, or as triple combination therapy with metformin and a sulfonylurea, or as add-on to insulin (with or without metformin). Contraindications:
Hypersensitivity to any component. Precautions: Not for Type 1 Diabetes Mellitus or diabetic ketoacidosis. Acute pancreatitis (discontinue treatment), renal insufficiency, hypoglycaemia in combination with a sulfonylurea or with insulin, hypersensitivity, bullous
pemphigoid (discontinue treatment). Pregnancy (Cat B3), lactation, children. Interactions: No clinically significant interactions observed with sitagliptin and metformin, glibenclamide, simvastatin, rosiglitazone, warfarin, oral contraceptives, digoxin or cyclosporine (see
full PI). Adverse reactions: URTI, headache, hypoglycaemia, nasopharyngitis. Postmarketing Experience: Hypersensitivity reactions, Acute pancreatitis, Worsening renal function (including acute failure), constipation, vomiting, headache, arthralgia, myalgia, pain in
extremity, back pain (see full PI). Dosage: 100 mg once daily with or without food. Adjust dose for moderate/severe renal insufficiency (see full PI). Consider reduced dose of sulfonylurea/insulin when used in combination. Based on PI amended: JANUVIA: 06 April 2017.
References: 1. JANUVIA Approved Product Information, April 2017. 2. Nauck MA et al. Diabetes Obes Metab 2007;9(2):194–205. 3. Barzilai N et al. Curr Med Res Opin 2011; 7(5):1049–58. 4. Arjona Ferreira JC et al. Am J Kidney Dis 2013;61(4): 579-587. 5. Chan
JCN et al. Diabetes Obes Metab 2008;10:545–555. 6. Arjona Ferreira JC et al. Diabetes Care 2013;36(5): 1067-1073. 7. Green JB et al. N Engl J Med 2015; 373(3): 232–242.
Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited.
Level 1, Building A, 26 Talavera Road, Macquarie Park NSW 2113. DIAB-1231002-0000. First Issued October 2017. Bloe Agency MSD12934. AD.15.9